The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.

In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the mRNA platform and how it quickens vaccine production

Moderna stock surged on Phase 3 mRNA cancer vaccine results with Merck, breaking key moving averages and hitting record RSI.

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based

Moderna dropped 10% after Wednesday's surge, crypto stocks rallied on Trump's legislation call, and Walmart fell 6% despite raising guidance Thursday.

Moderna and Merck’s first-of-its-kind cancer vaccine helped prevent the return of melanoma in a late-stage trial, and shares of both companies soared.

The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells